Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives [PDF]
The management of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after progression on osimertinib is becoming increasingly complex, particularly in Canada, where access to diagnostic testing and newer therapies ...
Nathalie Daaboul +16 more
doaj +2 more sources
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study. [PDF]
Background: Patients with visceral oligoprogressive and oligopersistent metastatic breast cancer (mBC) may benefit from metastasis-directed thermal ablation (TA) to all sites of metastasis, while maintaining the same systemic treatment, in order to delay
Bianco N +17 more
europepmc +2 more sources
First-line osimertinib in advanced [PDF]
Background: First-line osimertinib is standard for advanced EGFR -mutated non-small-cell lung cancer (NSCLC), but upfront combinations (FLAURA2, MARIPOSA) are reshaping this paradigm.
G. Suay +17 more
doaj +2 more sources
The Progression Patterns and Subsequent Treatments of First‐Line Immunotherapy in Advanced Non‐Small Cell Lung Cancer: A Retrospective Cohort Study [PDF]
Background In metastatic non‐small cell lung cancer (NSCLC) patients receiving first‐line immune checkpoint inhibitors (ICIs), the real‐world progression patterns and subsequent treatment outcomes remain controversial. Methods We retrospectively analyzed
Qi He +8 more
doaj +2 more sources
The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer [PDF]
Objectives: Patients with advanced stage non-small cell lung cancer (NSCLC) are generally considered incurable. The mainstay of treatment for these patients is systemic therapy.
Hartemink, K.J. +17 more
core +1 more source
Oligoprogression in Non-Small Cell Lung Cancer
We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing the same anticancer agents beyond progressive disease ...
Daijiro Harada, Nagio Takigawa
openaire +3 more sources
The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer [PDF]
Systemic treatment is standard for most types of cancer with disseminated metastases. The role of local treatment (LT) of individual tumor foci in patients with oligometastatic disease is unclear and the object of current scientific studies.This review is based on pertinent publications retrieved by a selective search in PubMed.Four randomized trials ...
Jan, Haussmann +5 more
openaire +2 more sources
For decades, the distant progression of breast cancer has been the purview of systemic therapy alone or with low to moderate-dose radiation therapy intended for the palliation of symptomatic metastases.
Gary M. Freedman +2 more
doaj +1 more source
Background: Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (
Wendi Xuzhang +5 more
doaj +1 more source
Stereotactic body radiotherapy for oligoprogressive cancer [PDF]
Stereotactic body radiotherapy (SBRT) is a focused tumour treatment that produces high local control rates with low toxicity. Its use in metastatic cancer is evolving rapidly, with purported benefits in the oligometastatic setting and for better palliation of symptomatic disease.
openaire +2 more sources

